Skip to Main Content

Paper Details

Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma.
J Clin Invest
38
2020
Dasatinib, Everolimus, H3K27M, HGG, HGG cells, HGGs, P-glycoprotein, PDGFR, PDGFR-driven glioma, PDGFRA, PPK, PPK tumor, Pediatric and adult, dasatinib, everolimus, glioma, high-grade gliomas, human, mTOR, mice, mouse, mutant PDGFRA, mutant TP53, patient, patients, primary HGG cells
Author NameAffiliation
Viveka Nand Yadav
Rodrigo T Cartaxo
Hugh J L Garton
Daniel R Wahl
Jann N SarkariaMayo Clinic College of Medicine
Cassie Kline
Cassie Kline
Cassie Kline
Cassie Kline
Sabine Mueller
Sabine Mueller
Sabine Mueller
Sabine Mueller
Theodore NicolaidesNYU Langone Medical Center
Sarah E S LearySeattle Children's Hospital/University of Washington (UW)
Sriram Venneti
Chandan Kumar-Sinha
Chandan Kumar-Sinha
Arul M Chinnaiyan
Arul M ChinnaiyanRogel Cancer Center
Arul M ChinnaiyanHoward Hughes Medical Institute.
Arul M ChinnaiyanMichigan Center for Translational Pathology.
Arul M Chinnaiyan
Arul M Chinnaiyan
Arul M Chinnaiyan
Arul M ChinnaiyanMichigan Center for Translational Pathology.
Arul M ChinnaiyanHoward Hughes Medical Institute.
Arul M ChinnaiyanRogel Cancer Center
Rajen Mody
Manjunath P Pai
Timothy N PhoenixUniversity of Cincinnati College of Pharmacy
Carl Koschmann
Carl Koschmann
  • 1 - 33

Datasets

Release 1.2